AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Salarius Pharmaceuticals Stock Trading Halted Pending News
ByAinvest
Saturday, Aug 16, 2025 9:54 am ET1min read
Salarius Pharmaceuticals (SLRX) trading has been halted due to pending news. No further information is available at this time.
Salarius Pharmaceuticals (SLRX) has seen its trading halted due to pending news, with no further information available at this time. The stock has been under scrutiny following several significant developments, including a reverse stock split and a merger with Decoy Therapeutics. The halt in trading is a common practice when companies have important news to disclose, allowing investors to digest the information before resuming trading.In the recent past, Salarius Pharmaceuticals has been actively working on its reverse stock split, which was announced on August 14, 2025. The company aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement by reducing its outstanding shares from approximately 7.6 million to 509,000 shares. This move is expected to take effect on August 18, 2025 [1].
Additionally, Salarius Pharmaceuticals has been making significant strides in its oncology drug development. The company has reported promising clinical trial results for its LSD1 inhibitor seclidemstat (SP-2577), which is currently being evaluated in a Phase 1/2 clinical study at MD Anderson Cancer Center for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [2]. The drug has shown supporting evidence in inhibiting LSD1, a validated target in cancer treatment.
Furthermore, Salarius Pharmaceuticals has announced a merger with Decoy Therapeutics, a private preclinical biopharmaceutical company. The merger, announced on January 13, 2025, aims to form a new entity focused on developing peptide conjugate therapeutics for respiratory viruses and cancer. The combined company will leverage Decoy's IMP3ACT™ platform for rapid drug design [3].
The pending news is likely related to these ongoing developments or other significant announcements that Salarius Pharmaceuticals may have in store. Investors are advised to monitor the situation closely and stay updated on any official communications from the company.
References:
[1] https://www.stocktitan.net/news/SLRX/
[2] https://www.stocktitan.net/news/SLRX/
[3] https://www.stocktitan.net/news/SLRX/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet